Lipid Management in Chronic Kidney Disease

Chronic kidney disease (CKD) ranks among the top five causes of global mortality, affecting approximately 35.5 million people in the United States (US). Despite being…

The Thyroid-Lipid Axis: Implications for Atherosclerosis and Beyond

Dyslipidemia frequently presents in individuals with thyroid dysfunction, attributed to the influence of thyroid hormones on various key metabolic pathways, thereby contributing to an elevated…

Lipid Management in Patients with Chronic Inflammatory Conditions

Immune system activation – i.e., systemic inflammation, plays an essential role in all stages of atherosclerosis, from the development of the fatty streak to acute…

Dyslipidemia and ASCVD in Non-White Ethnic, Racial, and Ancestral Groups

While atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia affect all populations, their impact is far from uniform. Many interwoven factors, including genetics, sociocultural determinants, and environmental…

The Lipid Panel – Coronary Artery Calcium

Obicetrapib Update

A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice

Secondary Causes of High Cholesterol